Dr. Hoos Discusses Key Points of the Ipilimumab Trial

Axel Hoos, MD, PhD
Published: Wednesday, Jun 15, 2011



Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses key points of the ipilimumab phase III trial looking at patients with untreated metastatic melanoma; a separate trial studied pretreated patients. The trial looked at the long-term survival in patients treated with ipilimumab with or without combination with dacarbazine. The combination therapy was more successful in terms of a survival benefit. Patients saw durable responses in the form of a shrinking tumor size for a median of 19 months compared to 8 months in the control; a PFS survival was also noted.
SELECTED
LANGUAGE


Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses key points of the ipilimumab phase III trial looking at patients with untreated metastatic melanoma; a separate trial studied pretreated patients. The trial looked at the long-term survival in patients treated with ipilimumab with or without combination with dacarbazine. The combination therapy was more successful in terms of a survival benefit. Patients saw durable responses in the form of a shrinking tumor size for a median of 19 months compared to 8 months in the control; a PFS survival was also noted.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x